Understanding The Function of RPL7: A Potential Drug Target Or Biomarker

Target Name: RPL7P1

NCBI ID: G6174

Other Name(s): RPL7_11_628 | ribosomal protein L7 pseudogene 1 | RPL17P | Ribosomal protein L7 pseudogene 1 | RPL7P

Understanding The Function of RPL7: A Potential Drug Target Or Biomarker

RPL7P1 (RPL7_11_628) is a gene that encodes a protein known as RPL7, which is a key regulator of the poly(ADP-ribose) polymerase (PARP) complex. PARP is a protein that helps maintain the stability of DNA by catalyzing the repair of DNA double-strand breaks. Mutations in the PARP gene have been linked to various diseases, including cancer, neurodegenerative diseases, and inherited disorders. Therefore, understanding the function of RPL7 and its potential as a drug target or biomarker is of great interest.

The RPL7 gene

The RPL7 gene is located on chromosome 11, at position 628. It encodes a protein that has 215 amino acid residues. The protein has a molecular weight of 21.1 kDa and a calculated pI of 5.9. The protein is expressed in various cell types, including muscle, nerve, heart, and liver cells. It is also found in the cytoplasm of human capacitated neurons, which are a type of nerve cell that have lost their mitochondria.

The function of RPL7

RPL7 is a key regulator of the PARP complex, which is responsible for repairing damaged DNA in the cell. The PARP complex is a protein that consists of several subunits, including the catalytic subunit alpha (伪), the regulatory subunit beta (尾), and the scaffold subunit alpha (纬). These subunits work together to ensure that damaged DNA is repaired by adding the appropriate base to the double-strand break.

RPL7 is the only known protein that belongs to the RPL7 family and is responsible for regulating the PARP complex. It is a 25 kDa protein that has a monomeric structure. The protein has a N-terminal region that contains a putative nucleotide-binding domain (NBD), which is known to play a role in protein-DNA interactions. The C-terminus of the protein contains a regions of acidic amino acids (pKa) that are involved in protein-protein interactions.

The role of RPL7 in DNA repair

RPL7 is involved in the repair of DNA double-strand breaks by catalyzing the addition of adenosine to the double-strand break. Adenosine is a purine nucleotide that can act as a base for the repair process. RPL7 uses the enzyme-mediated repair mechanism, which involves the transfer of an adenine base from the damaged strand to the complementary strand.

In addition to its role in DNA repair, RPL7 is also involved in the regulation of the PARP complex. It has been shown to interact with several subunits of the PARP complex, including the alpha subunit and the gamma subunit. These interactions may play a role in regulating the activity of the PARP complex and in the regulation of DNA repair.

Potential as a drug target or biomarker

The RPL7 gene has been identified as a potential drug target or biomarker due to its involvement in various diseases. The RPL7 gene has been associated with various diseases, including cancer, neurodegenerative diseases, and inherited disorders. Therefore, the study of RPL7 and its potential as a drug target or biomarker is of great interest.

In cancer, RPL7 has been shown to be involved in the regulation of cell proliferation and apoptosis. Several studies have shown that RPL7 levels are increased in various types of cancer, including breast, ovarian, and colorectal cancers. Therefore, RPL7 may be a useful biomarker for cancer diagnosis and treatment.

In neurodegenerative diseases, RPL7 has been shown to be involved in the regulation of neurotransmitter synthesis and function. Several studies have shown that RPL7 levels are decreased in various types of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, RPL7 may be a useful biomarker for neurodegenerative diseases.

Inherited disorders, such

Protein Name: Ribosomal Protein L7 Pseudogene 1

More Common Targets